News and Press Releases

SeaBeLife secures €2 million

This funding will help fast-track the launch of clinical trials in dry AMD and severe acute hepatitis programs 1 October 2025 -- Roscoff, France -- SeaBeLife, a biotechnology company developing...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 1, 2025

Place Georges Teissier 29680 ROSCOFF

PACE launches its third funding round today, supporting innovative projects that tackle resistant bacterial infections posing the greatest threat to global health

1 October 2025 -- Alderley Park, UK -- To stay ahead of the escalating antibiotic resistance crisis, we need bold thinking and transformative innovation. According to the World Health Organization...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 1, 2025

Bioxodes secures new funds to reach early 2025 milestones and pursue Series B financing

Bioxodes raises €2.7 million from existing investors in Series A extension Interim data from BIRCH intracerebral hemorrhage (ICH) Phase 2a trial in Q1 2025 Recruitment of up to 16 additional...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 12, 2025

Parc d'activités Aéropole Rue Santos-Dumont, 1 6041 Gosselies, Belgique

Glox Therapeutics Awarded Share of £3M Collaborative Discovery Programme Funding from Cystic Fibrosis Antimicrobial Resistance Syndicate

£500K grant to advance discovery and development of effective precision antibiotics targeting antimicrobial-resistant lung infections in people with cystic fibrosis Programme delivered by CF AMR Syndicate offers cross-sector collaboration and...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 21, 2025

11 The Square University Of Glasgow University Avenue Glasgow G12 8QQ

ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue® Therapeutics

Brings 2024 Funding Round Total to €24m 16 December 2024 -- Milan, Italy -- BetaGlue Therapeutics S.p.A, an Italian clinical-stage oncology company developing an innovative radiotherapy platform for the targeted...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: December 16, 2024

BetaGlue Therapeutics SpA. Piazzetta Umberto Giordano 4, 20122 Milan, Italy

Deep Science Ventures and General Inception collaborate to create fibrosis-focused therapeutics company

12 December 2024 – London, UK, and Palo Alto, CA, US – Deep Science Ventures, a UK-based venture studio, and General Inception, a US-based venture studio, today announced a collaboration...

Category: Drug Discovery, Other
Posted: December 12, 2024

Centauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives

Funding to support further development of lead programme for a novel therapeutic targeting Gram-negative bacteria including Multi-Drug-Resistant strains Optimisation will also support application of the Alphamer® platform across other therapeutic...

Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: November 25, 2024

Discovery Park, Sandwich CT13 9ND

Discover the Power of AI in Biopharma: TVM to host thought-provoking sessions at BIO-Europe 2024

30 October 2024 – Munich, Germany and Montreal, Quebec, Canada – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today...

Category:
Posted: October 31, 2024

TVM Capital GmbH, TVM Life Science Management GmbH, Ottostraße 4, 80333 Munich, Germany

Antiverse raises £3.5M ($4.6M) to advance generative AI antibody design platform

Increases total equity financing raised to £7.2M ($10.1M) New facilities in Boston and Prague will provide increased capacity to deliver pipeline of pharma and biotech projects Funding to progress internal...

Category: Biotechnology, Drug Discovery
Posted: October 17, 2024

MediCentre, Heath Park, Cardiff CF14 4UJ

ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement

Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications 04 September 2024 – Dublin, Ireland, and Cheshire, UK – ERS...

Category: BioManufacturing
Posted: September 9, 2024

8th Floor, Block E, Iveagh Court, Harcourt Road, Dublin D02 YT22, Ireland

Nxera Pharma Receives US$10m from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone

27 June 2024, Tokyo, Japan and Cambridge, UK - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration...

Category: BioManufacturing, Other, Pharmaceutical
Posted: June 28, 2024

Midtown East 9-7-2 Akasaka Minato-ku Tokyo 107-0052

Oxford Drug Design and CRUK Scotland Institute awarded MRC grant funding to advance novel cancer therapeutics discovery

Collaboration to use genetically engineered mouse models to validate a new approach to cancer therapy 4 June 2024 - United Kingdom - The CRUK (Cancer Research UK) Scotland Institute and Oxford...

Category: Drug Discovery
Posted: June 10, 2024

Oxford Drug Design Lt,d Oxford Centre for Innovation, New Road, Oxford, OX1 1BY, UK

Owlstone Medical Secures $6.5m to Support Development of Breath-based Diagnostics for Infectious Disease

$5m equity investment and initial $1.5m grant funding committed by the Bill & Melinda Gates Foundation for development of breath-based diagnostic solutions to improve outcomes in the developing world Funding...

Category: Biotechnology, Other
Posted: April 25, 2024

Owlstone Ltd, 127 Cambridge Science Park, Milton Road, Cambridge, CB4 0GD, UK

Eisbach and Cancer Focus Fund Announce $4.5m Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumours

Eisbach is enabling the potential of synthetic lethality by developing novel compounds to exploit molecular vulnerabilities uniquely present in many hard-to-treat cancers 21 March 2024 -- Martinsried, Germany and Texas, US...

Category: Biotechnology, Pharmaceutical
Posted: March 21, 2024

Am Klopferspitz 19, 82152 Planegg, Germany

Calluna Pharma launches and announces €75m Series A financing to develop novel therapies for inflammatory and fibrotic diseases

Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics Calluna Pharma has a pipeline of selective antibodies targeting immunological diseases New company to complete multiple clinical...

Category: Drug Discovery, Pharmaceutical
Posted: January 23, 2024

Nytt Foretak AS, Grundingen 6, 0250 Oslo, Norway.